Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, placebo-controlled, randomized study of fosbretabulin
given with chemotherapy (paclitaxel and carboplatin) compared to placebo given with
chemotherapy (paclitaxel and carboplatin) in subjects with anaplastic thyroid cancer (ATC).
The primary objective of the study is to determine overall survival. A maximum of 300
subjects will be recruited from approximately 75 multinational sites of which approximately
35 will be located in the United States.